1.
Clin Exp Dermatol
; 46(8): 1558-1560, 2021 Dec.
Article
in English
| MEDLINE
| ID: mdl-34137070
ABSTRACT
Pyoderma gangrenosum (PG) is an autoinflammatory neutrophilic dermatosis characterized by rapidly enlarging, painful ulcers. Anakinra is a recombinant interleukin (IL)-1 receptor antagonist that blocks the activity of IL-1α and IL-1ß by competitively inhibiting IL-1 binding to the IL-1 type 1 receptor. We present a series of two patients with recalcitrant PG, who had limited therapeutic options and multiple comorbidities and multiple previous treatment failures, who obtained 100% healing with anakinra. Compared with conventional first-line therapies for PG, the safety profile of anakinra may be preferable for patients with multiple comorbidities. Further research is needed to assess the safety and efficacy of anakinra for PG.
Subject(s)
Dermatologic Agents/therapeutic use , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Pyoderma Gangrenosum/drug therapy , Aged , Antiphospholipid Syndrome/complications , Arthritis, Rheumatoid/complications , Dermatologic Agents/adverse effects , Dyslipidemias/complications , Female , Humans , Hypertension/complications , Interleukin 1 Receptor Antagonist Protein/adverse effects , Middle Aged , Obesity/complications , Peripheral Vascular Diseases/complications , Pyoderma Gangrenosum/complications , Renal Insufficiency, Chronic/complications
2.
Br J Dermatol
; 183(4): 767-768, 2020 10.
Article
in English
| MEDLINE
| ID: mdl-32294243
3.
Br J Dermatol
; 182(5): 1290-1291, 2020 05.
Article
in English
| MEDLINE
| ID: mdl-31715016
4.
Clin Exp Dermatol
; 45(2): 273-274, 2020 Mar.
Article
in English
| MEDLINE
| ID: mdl-31389065